Please select the eligibility criteria that correspond to the clinical trial below.
Title: Induction of Labour in Pre-eclamptic Women: a Randomised Trial Comparing the Foley Balloon Catheter With Oral Misoprostol
Brief Summary: Between 40,000 and 80,000 pregnant women die annually from pre-eclampsia and eclampsia. Magnesium sulphate and anti-hypertensive therapies can reduce the morbidity associated with pre-eclampsia. The only cure, however, comes with delivery. Prompt delivery of the baby, preferably by vaginal route, is vital in order to achieve good maternal and neonatal outcomes. Induction of labour is therefore a critical intervention in order to prevent morbidity to both mother and baby. Two low cost interventions - oral misoprostol tablets and transcervical Foley catheterization - are already used by some in low resource settings, but their relative risks and benefits are not known. These interventions could optimize the care pathway for women needing induction of labour. This is especially important in low resource settings where improvement is most needed and the potential to reduce the maternal and neonatal mortality and morbidity is the greatest. The ideal induction agent would result in a relatively short induction to delivery interval without risk to fetus and with low rates of emergency caesarean section. The induction to delivery interval is especially important in pre-eclampsia and eclampsia where the condition may deteriorate rapidly until delivery. Inductions with prostaglandins, including misoprostol, are sometimes associated with uterine hyperstimulation and consequent fetal hypoxia, whilst the effectiveness and safety of Foley catheter as an induction agent has been persistently questioned. This study will identify the risk, benefits and trade-offs in efficacy, safety, acceptability and cost of these two low cost induction methods.


Options:
A: Inclusion Criteria:

* Indication for labour induction
* Term pregnancy with alive fetus
* Bishop score less than six

Exclusion Criteria:

* Age less than 18 years
* Previous uterine scar
* Nonvertex presentation
* Non-reassuring fetal status
* Fetal anomalies
* Fetal growth restriction
* Genital bleeding
* Tumors, malformations and/or ulcers of vulva, perineum or vagina
B: Inclusion Criteria:

* Ongoing pregnancies with a live fetus in whom the decision has been made to induce vaginal delivery because of preeclampsia or uncontrolled hypertension. Women will be included irrespective of whether an intrapartum caesarean section on fetal grounds or would be considered or not.
* Women age ≥18 years
* Signed informed consent form

Exclusion Criteria:

* • Women with previous caesarean sections

  * Those unable to give informed consent
  * Multiple pregnancy
  * History of allergy to misoprostol
  * Ruptured membranes
  * Chorioamnionitis (by clinical diagnosis)
C: Inclusion Criteria:

* Women over 18
* single pregnancy
* cephalic presentation
* intact membranes
* unfavorable cervix ( less than 6 Bishop )
* CTGR not reactive decelerative
* Signed informed consent by the patient.

Exclusion Criteria:

* prior Cesarean section or previous uterine surgery .
* Allergy or intolerance to any of the study drugs
* stillbirth
* uterine growth restricted fetuses
* contraindication for vaginal delivery
* Anterior placenta
* Multiparity
* moderate to severe heart disease
* hypertensive disorders of pregnancy
* Suspected chorioamnionitis
* Coagulation disorders
* history of epileptic seizures
* liver or kidney disease
* Cognitive impairment or bad knowledge of Spanish
D: Inclusion Criteria:

* 34 to 42 weeks of gestation
* live singleton
* Bishop score \< or = 6
* reassuring fetal heart beat pattern

Exclusion Criteria:

* nonreassuring fetal heart beat pattern
* parity ovr five
* any contraindication to labor and/or vaginal delivery
* uterine scar
* suspected placental abruption with abnormal FHR pattern
* vaginal bleeding other than "bloody show"
* cervical dilatation of \> or = 4 cm
* uterine contractions \> or = 3 in 10 minutes
* significant maternal cardiac, renal or hepatic disease
* hypersensitivity to misoprostol or prostaglandin analogs

Answer: B